Timing of start of systemic treatment in patients with asymptomatic metastasized pancreatic cancer (TIMEPAN): a protocol of a multicenter prospective patient preference non-randomized trial

Delayed Versus Immediate Start of Chemotherapy in Asymptomatic Patients With Advanced Cancer: A Meta-Analysis

(2023) Simone Augustinus et al.   ONCOLOGIST

The fear of cancer recurrence and progression in patients with pancreatic cancer

(2022) Esther N. Pijnappel et al.   SUPPORTIVE CARE IN CANCER

Timing of onset of systemic treatment in asymptomatic patients with metastatic pancreatic cancer: An international expert survey and case-vignette study.

(2022) Simone Augustinus et al.   JOURNAL OF CLINICAL ONCOLOGY

STROBE Reporting Guidelines for Observational Studies

(2021) Amir A. Ghaferi et al.   JAMA Surgery

Pancreatic Cancer

(2021) Wungki Park et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands

(2020) Lois A. Daamen et al.   ANNALS OF SURGERY

Postoperative surveillance of pancreatic cancer patients

(2019) L.A. Daamen et al.   EJSO

Comparison of FDG-PET/CT for Cancer Detection in Populations With Different Risks of Underlying Malignancy

(2019) HUNG-PIN CHAN et al.   IN VIVO

RECIST 1.1—Update and clarification: From the RECIST committee

(2016) Lawrence H. Schwartz et al.   EUROPEAN JOURNAL OF CANCER

Factors influencing participation in a randomized controlled resistance exercise intervention study in breast cancer patients during radiotherapy

(2015) Sandra M Gollhofer et al.   BMC CANCER

Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase

(2015) D Di Gioia et al.   BRITISH JOURNAL OF CANCER

Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies

(2015) Peter C. Austin et al.   STATISTICS IN MEDICINE

Discontinuation and non-publication of surgical randomised controlled trials: observational study

(2014) S. J. Chapman et al.   BMJ-British Medical Journal

The prognostic role of time to diagnosis and presenting symptoms in patients with pancreatic cancer

(2013) Paolo G. Gobbi et al.   Cancer Epidemiology

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial

(2012) Sophie Gourgou-Bourgade et al.   JOURNAL OF CLINICAL ONCOLOGY

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)

(2011) M. Herdman et al.   QUALITY OF LIFE RESEARCH

Clinical presentation and waiting time targets do not affect prognosis in patients with pancreatic cancer

(2010) Dimitri A. Raptis et al.   SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND

Disappointment and drop-out rate after being allocated to control group in a smoking cessation trial

(2009) D. Lindström et al.   Contemporary Clinical Trials

Cancer patient preferences for quality and length of life

(2008) Neal J. Meropol et al.   CANCER